Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma

Pharmacogenomics

Volumn 12, Issue 4, 2011, Pages 535-546

  Chetty, Chandramu ^a   Rao, Jasti S ^a   Lakka, Sajani S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

haplotype; matrix metalloproteinases; MMP; non small cell lung carcinoma; NSCLC; pharmacogenomics; polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; COLLAGENASE 3; ERLOTINIB; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 26; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TANOMASTAT;

ARTICLE; CANCER RADIOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GLIOBLASTOMA; HAPLOTYPE; HUMAN; INDEL MUTATION; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MUSCULOSKELETAL DISEASE; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PHARMACOGENOMICS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CARCINOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 79955542546     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.207     Document Type: Article

References (59)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Scagliotti G, Novello S: Adjuvant chemotherapy after complete resection for early stage NSCLC. Lung Cancer 42(Suppl. 1), S47-S51 (2003). (Pubitemid 37378186)
3. Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8(3), 221-233 (2007).
4. Overall CM, Kleifeld O: Tumour microenvironment -opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6(3), 227-239 (2006). (Pubitemid 43292566)
5. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2(3), 161-174 (2002). (Pubitemid 37328786)
6. Cho NH, Hong KP, Hong SH, Kang S, Chung KY, Cho SH: MMP expression profiling in recurred stage IB lung cancer. Oncogene 23(3), 845-851 (2004). (Pubitemid 38241286)
7. Delebecq TJ, Porte H, Zerimech F et al.: Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin. Cancer Res. 6(3), 1086-1092 (2000). (Pubitemid 30159371)
8. Hofmann HS, Hansen G, Richter G et al.: Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin. Cancer Res. 11(3), 1086-1092 (2005). (Pubitemid 40175757)
9. Muller D, Breathnach R, Engelmann A et al.: Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int. J. Cancer 48(4), 550-556 (1991).
10. Pritchard SC, Nicolson MC, Lloret C et al.: Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol. Rep. 8(2), 421-424 (2001). (Pubitemid 33758105)
11. Shah SA, Spinale FG, Ikonomidis JS, Stroud RE, Chang EI, Reed CE: Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J. Thorac. Cardiovasc. Surg. 139(4), 984-990 (2010).
12. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M: Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP?-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int. J. Cancer 64(5), 355-359 (1995).
13. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87(2), 161-167 (2002).
14. Bramhall SR, Hallissey MT, Whiting J et al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer 86(12), 1864-1870 (2002).
15. Fingleton B: Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin. Ther. Targets 7(3), 385-397 (2003). (Pubitemid 36722223)
16. Sherry ST, Ward M, Sirotkin K: dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 9(8), 677-679 (1999). (Pubitemid 29412785)
17. Ponomarenko JV, Orlova GV, Merkulova TI et al.: rSNP-Guide: an integrated database-tools system for studying SNPs and site-directed mutations in transcription factor binding sites. Hum. Mutat. 20(4), 239-248 (2002).
18. Ye S: Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 19(7), 623-629 (2000).
19. Tower GB, Coon CC, Benbow U, Vincenti MP, Brinckerhoff CE: Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP?-1 promoter in melanoma cells. Biochim. Biophys. Acta 1586(3), 265-274 (2002). (Pubitemid 34457921)
20. Su L, Zhou W, Park S et al.: Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 14(3), 567-570 (2005). (Pubitemid 40489196)
21. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol. 190(2), 150-156 (2000). (Pubitemid 30082487)
22. Zhang WQ, Lin H, Zhou YA, Wang YJ, Cheng QS: [Association of MMP1 -1607(1G2G)single nucleotide polymorphism with susceptibility to lung cancer in Northwestern Chinese population of Han nationality]. Zhonghua. Yi Xue Yi Chuan Xue Za Zhi. 23(3), 313-315 (2006). (Pubitemid 43937915)
23. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 61(21), 7825-7829 (2001). (Pubitemid 33049371)
24. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D: Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res. 64(20), 7622-7628 (2004). (Pubitemid 39372109)
25. Yu C, Pan K, Xing D et al.: Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 62(22), 6430-6433 (2002). (Pubitemid 35364100)
26. Zhou Y, Yu C, Miao X et al.: Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 26(6), 1117-1121 (2005). (Pubitemid 41214305)
27. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM: Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 271(22), 13055-13060 (1996). (Pubitemid 26175880)
28. Fang S, Jin X, Wang R et al.: Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 26(2), 481-486 (2005). (Pubitemid 40246571)
29. Fang SM, Jin X, Li Y et al.: [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer]. Ai. Zheng. 24(3), 305-310 (2005).
30. Jormsjo S, Whatling C, Walter DH, Zeiher AM, Hamsten A, Eriksson P: Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 21(11), 1834-1839 (2001). (Pubitemid 34219789)
31. Zhang J, Jin X, Fang S et al.: The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 26(10), 1748-1753 (2005). (Pubitemid 41487990)
32. Zhang B, Ye S, Herrmann SM et al.: Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99(14), 1788-1794 (1999). (Pubitemid 29181405)
33. Rollin J, Regina S, Vourc'h P et al.: Influence of MMP?2 and MMP?9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 56(2), 273-280 (2007). (Pubitemid 46591988)
34. Wang Y, Fang S, Wei L et al.: No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer 49(2), 155-161 (2005). (Pubitemid 40966742)
35. Balbin M, Fueyo A, Tester AM et al.: Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 35(3), 252-257 (2003). (Pubitemid 37363179)
36. Montel V, Kleeman J, Agarwal D, Spinella D, Kawai K, Tarin D: Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res. 64(5), 1687-1694 (2004). (Pubitemid 38428690)
37. Yoon S, Kuivaniemi H, Gatalica Z et al.: MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black males. Matrix Biol. 21(6), 487-498 (2002). (Pubitemid 35248274)
38. González-Arriaga P, Lopez-Cima MF, Fernandez-Somoano A et al.: Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk. BMC Cancer 19(8), 378 (2008).
39. Hu Z, Huo X, Lu D et al.: Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin. Cancer Res. 11(15), 5433-5439 (2005). (Pubitemid 41060818)
40. Jin G, Miao R, Hu Z et al.: Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population. Int. J. Cancer 124(9), 2172-2178 (2009).
41. Su L, Zhou W, Asomaning K et al.: Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 27(5), 1024-1029 (2006).
42. Sauter W, Rosenberger A, Beckmann L et al.: Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol. Biomarkers Prev. 17(5), 1127-1135 (2008).
43. Sun T, Gao Y, Tan W et al.: Haplotypes in matrix metalloproteinase gene cluster on chromosome 11q22 contribute to the risk of lung cancer development and progression. Clin. Cancer Res. 12(23), 7009-7017 (2006). (Pubitemid 44974497)
44. McColgan P, Sharma P: Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int. J. Cancer 125(6), 1473-1478 (2009).
45. Heist RS, Marshall AL, Liu G et al.: Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin. Cancer Res. 12(18), 5448-5453 (2006). (Pubitemid 44497260)
46. Scherf DB, Dally H, Muller P et al.: Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis. Eur. Respir. J. 35(2), 381-390 (2010).
47. Galligioni E, Ferro A: Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer 34(Suppl. 4) S3-S7 (2001).
48. Reckamp KL, Gardner BK, Figlin RA et al.: Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J. Thorac. Oncol. 3(2), 117-124 (2008). (Pubitemid 351323184)
49. Aljada IS, Ramnath N, Donohue K et al.: Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3218-3229 (2004). (Pubitemid 41103676)
50. Dubinett SM, Elashoff D, Meyerson M: Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture? J. Clin. Oncol. 22(16), 3209-3211 (2004). (Pubitemid 41103673)
51. Gouyer V, Conti M, Devos P et al.: Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 103(8), 1676-1684 (2005). (Pubitemid 40490029)
52. Ylisirnio S, Hoyhtya M, Makitaro R et al.: Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin. Cancer Res. 7(6), 1633-1637 (2001). (Pubitemid 32708629)
53. Blons H, Gad S, Zinzindohoue F et al.: Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin. Cancer Res. 10(8), 2594-2599 (2004). (Pubitemid 38509131)
54. Han MK, Postma D, Mannino DM et al.: Gender and chronic obstructive pulmonary disease: why it matters. Am. J. Respir. Crit. Care Med. 176(12), 1179-1184 (2007). (Pubitemid 350256470)
55. Mannino DM: COPD and lung cancer have come a long way .baby. Am. J. Respir. Crit. Care Med. 176(2), 108-109 (2007) (Pubitemid 47057843)
56. Nenan S, Boichot E, Lagente V, Bertrand CP: Macrophage elastase (MMP?-12): a pro-inflammatory mediator? Mem. Inst. Oswaldo Cruz 100(Suppl. 1), 167-172 (2005). (Pubitemid 40685458)
57. Gorrin Rivas MJ, Arii S, Furutani M et al.: Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology 28(4), 986-993 (1998). (Pubitemid 28450259)
58. Houghton AM, Grisolano JL, Baumann ML et al.: Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 66(12), 6149-6155 (2006).
59. Inuzuka K, Ogata Y, Nagase H, Shirouzu K: Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J. Surg. Res. 93(2), 211-218 (2000).